Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi, Regeneron lose bid to overturn Amgen win in patent case

A federal judge refused to throw out a court verdict upholding two Amgen patents related to its cholesterol drug, a defeat for Sanofi and Regeneron Pharmaceuticals, which make a rival drug.

Read More »

Ophthotech Clinical Disaster Spurs Layoffs

Ophthotech is cutting up to 135 jobs following the failure of its two Phase III clinical trials combining the company’s Fovista and Genentech’s Lucentis to treat wet AMD.

Read More »

Allergan to buy Acelity’s tissue unit LifeCell

Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.

Read More »

Akebia sells rights to anemia drug to Otsuka

Drug developer Akebia Therapeutics Inc. said it had signed a co-development and marketing deal worth up to $1 billion with Japan’s Otsuka Holdings Co. Ltd.

Read More »

Mylan launches EpiPen generic at $300 per 2-pack

Mylan, which has come under fire for its drug pricing, will sell a generic version of its life-saving EpiPen allergy treatment at a more than 50 percent discount.

Read More »

Lonza to buy Capsugel from KKR for $5.5 billion

Lonza Group announced its biggest-ever acquisition with a deal to buy Capsugel, a U.S. maker of capsule products and other drug delivery systems, for $5.5 billion in cash to broaden its product range as a pharmaceuticals industry supplier.

Read More »

Medical device maker Teleflex to buy Vascular Solutions for $1 billion

Teleflex Inc. agreed to buy fellow medical device maker Vascular Solutions Inc. for about $1 billion.

Read More »

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

Read More »

Arrowhead Pharma shelves three drug programs

Shares of Arrowhead Pharmaceuticals Inc. sank one day after the company said it would stop developing all drugs being tested on humans.

Read More »

Bone Therapeutics Taps New CEO

Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom